908 Devices (MASS) Set to Announce Earnings on Tuesday

908 Devices (NASDAQ:MASS) is scheduled to release its earnings data before the market opens on Tuesday, April 30th. Analysts expect 908 Devices to post earnings of ($0.37) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

908 Devices (NASDAQ:MASS) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.03. 908 Devices had a negative net margin of 72.47% and a negative return on equity of 21.09%. The business had revenue of $14.40 million during the quarter, compared to the consensus estimate of $14.16 million. During the same quarter in the prior year, the firm earned ($0.31) EPS. The firm’s revenue was up 24.1% compared to the same quarter last year. On average, analysts expect 908 Devices to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

908 Devices Stock Performance

Shares of NASDAQ MASS opened at $5.67 on Monday. 908 Devices has a 52-week low of $4.85 and a 52-week high of $12.51. The firm has a 50 day moving average price of $6.65 and a two-hundred day moving average price of $7.08.

Insider Buying and Selling at 908 Devices

In other 908 Devices news, CEO Kevin J. Knopp sold 9,071 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $7.00, for a total value of $63,497.00. Following the completion of the transaction, the chief executive officer now directly owns 411,981 shares in the company, valued at approximately $2,883,867. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other 908 Devices news, CEO Kevin J. Knopp sold 9,071 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $7.00, for a total value of $63,497.00. Following the completion of the transaction, the chief executive officer now directly owns 411,981 shares in the company, valued at approximately $2,883,867. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Joseph H. Iv Griffith sold 5,698 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $7.00, for a total transaction of $39,886.00. Following the sale, the chief financial officer now owns 89,711 shares of the company’s stock, valued at $627,977. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,001 shares of company stock worth $139,955. 27.80% of the stock is currently owned by company insiders.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.